Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NanoPep4IBD

Financiado

Cerrado

Novel gut-stable peptides and drug-delivery systems - possible treatment for IBD

Inflammatory bowel diseases (IBD) affect more than 2 million residents in Europe. Currently, there is no cure for IBD, and treatment focuses on alleviating symptoms. Injured/compromised mucosal barrier and GI biofilms are common p... ver más

31/08/2025

UNIVIE

Presupuesto desconocido

Líder del proyecto

UNIVERSITAT WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-09-01

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UNIVIE

Lider

Proyectos interesantes

TRANS-INT

Medical Technol...

Nanotechnology

11M€ Cerrado

SAF2016-79230-R

Medical Technol...

Nanotechnology

97K€ Cerrado

BiofilmEradicate

Medical Technol...

Nanotechnology

150K€ Cerrado

HsrELPnano

Medical Technol...

Nanotechnology

188K€ Cerrado

RTI2018-099227-B-I00

Medical Technol...

Nanotechnology

182K€ Cerrado

FORMAMP

Medical Technol...

Nanotechnology

10M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2023-09-01
Fecha Fin: 2025-08-31

Líder del proyecto

UNIVERSITAT WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Inflammatory bowel diseases (IBD) affect more than 2 million residents in Europe. Currently, there is no cure for IBD, and treatment focuses on alleviating symptoms. Injured/compromised mucosal barrier and GI biofilms are common pathophysiological deviations in IBD. The overall aim of this project is to develop gut-stable peptides effective against biofilms, peptides suitable for wound-healing treatment, and nanocarrier systems for targeted delivery. In particular, I will focus on developing new antibiofilm peptides, based on the existent cathelicidins, and also develop GI wound-healing peptides based on the trefoil factor family (TFF). Cathelicidins and TFF peptides occur naturally in humans, and defects in these response systems can lead to GI diseases. Hence, in this project I aim to: (i) design, synthesize and characterise novel gut-stable antibiofilm and wound-healing peptides, and (ii) develop nanoparticle drug-delivery systems for their targeted application. Based on peptidomimetic synthesis, I will produce peptides containing unnatural amino acids, loop and helix mimetics, and also retroinverso analogues. Chitosan-coated liposomal and silica nanoparticles will be used for targeted colon treatment, as multifunctional systems: nanocarriers protect the peptides, chitosan enables mucoadhesive release, and chitosan has also beneficial anti-inflammatory, wound-healing and antimicrobial effects on its own. High regioselectivity and limited off-target effects can be achieved by using gut-stable peptides targeting local sites of inflammation, compromised gut epithelium and biofilms, since they are too large to cross the gut barrier. Orally administered peptide drugs targeting colonic tissues represent a highly innovative and safe route in treating GI disorders.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores